123 related articles for article (PubMed ID: 20838878)
1. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J
Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878
[TBL] [Abstract][Full Text] [Related]
2. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
3. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
[TBL] [Abstract][Full Text] [Related]
4. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
[TBL] [Abstract][Full Text] [Related]
5. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.
Akbari MR; Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Zhang S; Narod SA; Hurley J
Clin Genet; 2014 Jan; 85(1):64-7. PubMed ID: 23458327
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
8. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
9. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
[TBL] [Abstract][Full Text] [Related]
10. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
Blecharz P; Szatkowski W; Klimek M; Urbański K
Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
[TBL] [Abstract][Full Text] [Related]
11. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Couch FJ; DeShano ML; Blackwood MA; Calzone K; Stopfer J; Campeau L; Ganguly A; Rebbeck T; Weber BL
N Engl J Med; 1997 May; 336(20):1409-15. PubMed ID: 9145677
[TBL] [Abstract][Full Text] [Related]
14. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Francis W; Halliday D; Royer R; Zhang S; Li S; Thompson I; Donenberg T; Hurley J; Akbari MR; Narod SA
Clin Genet; 2016 Mar; 89(3):328-31. PubMed ID: 25920394
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
Sarantaus L; Vahteristo P; Bloom E; Tamminen A; Unkila-Kallio L; Butzow R; Nevanlinna H
Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E
Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018
[TBL] [Abstract][Full Text] [Related]
19. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
